<DOC>
	<DOCNO>NCT01469273</DOCNO>
	<brief_summary>This interventional trial shall investigate efficacy tolerance suspension non-pathogenic probiotic E. coli strain Nissle ( EcN ) prophylaxis gastrointestinal infection newborn infant . ECN-SUSPENSION probiotic contain viable E. coli bacteria non-pathogenic Nissle 1917 strain concentration 10exp8 cell per ml .</brief_summary>
	<brief_title>Prophylaxis Gastrointestinal Infections With EcN</brief_title>
	<detailed_description>Newborns ( treatment-group E ) infants age 6 month ( treatment-group L ) shall treat 1 x 1 ml ECN-SUSPENSION 10 day observe age 12 months.Treatment-group E ( newborn ) receive EcN-Suspension first 10 day life observe next 12 month . Treatment-group L ( infant age 6 month ) receive EcN-Suspension first 10 day seventh month life observe next 6 months.The correspond control group remain untreated observe 12 month . According hospital daily routine inclusion exclusion criterion check . All newborn meet inclusion criterion include trial . Patients ' anamnestic data general health status record initial control.Controls perform accord time schedule normally use hospital function trial site . According , monthly control data efficacy safety record . The final control assess tolerance efficacy trial medication conduct along physical examination observation period 12 months.In study , diarrhea define increase stool frequency &gt; 3 watery loose stool 24 hour least two consecutive days.The prophylaxis gastrointestinal infection EcN-Suspension expect result decrease number episode diarrhea comparison untreated control . The primary efficacy criterion number episode diarrhea cause gastrointestinal infection within first 12 month .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Diarrhea , Infantile</mesh_term>
	<criteria>Informed consent form sign patient 's parent legal guardian . Term born infant . Age &lt; 2 day Gestational age 3842 week gestation Birth weight 25003750 gr . Normal delivery ( eutocia ) Exclusion criterion : Simultaneous participation another clinical study Consumption food supplement medicine contain live microorganism metabolic product component study Other reason opinion investigator provide reason inclusion patient study . Autoimmune diseaseÂ·Severe sepsis severe systemic injury Immunosuppressive treatment Severe comorbidities disease : Heart Liver Kidney Genetic disease Other serious associate disease , opinion investigator , cast doubt implementation test accord study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Diarrhea</keyword>
	<keyword>EcN</keyword>
	<keyword>E. coli strain Nissle 1917</keyword>
	<keyword>Gastrointestinal infection</keyword>
	<keyword>Infant</keyword>
	<keyword>Newborn</keyword>
	<keyword>Probiotic drug</keyword>
	<keyword>Prevention</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>